238 related articles for article (PubMed ID: 29700766)
1. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
2. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
[TBL] [Abstract][Full Text] [Related]
4. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
B A; D N; Veerabrahma K
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):126-137. PubMed ID: 28290712
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
6. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
Jain S; Patel K; Arora S; Reddy VA; Dora CP
Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
[TBL] [Abstract][Full Text] [Related]
7. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Kaithwas V; Dora CP; Kushwah V; Jain S
Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
[TBL] [Abstract][Full Text] [Related]
8. Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil.
Khattab WM; Zein El-Dein EE; El-Gizawy SA
Drug Dev Ind Pharm; 2020 May; 46(5):795-805. PubMed ID: 32275456
[No Abstract] [Full Text] [Related]
9. Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Elshafeey AH; El-Dahmy RM
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834284
[TBL] [Abstract][Full Text] [Related]
10. Development and Evaluation of an Anti-Epileptic Oral Fast-Dissolving Film with Enhanced Dissolution and In vivo Permeation.
Soroushnai A; Ganji F; Vasheghani-Farahani E; Mobedi H
Curr Drug Deliv; 2018; 15(9):1294-1304. PubMed ID: 30033870
[TBL] [Abstract][Full Text] [Related]
11. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
12. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
[TBL] [Abstract][Full Text] [Related]
13. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.
Albash R; El-Nabarawi MA; Refai H; Abdelbary AA
Int J Nanomedicine; 2019; 14():6555-6574. PubMed ID: 31616143
[TBL] [Abstract][Full Text] [Related]
14. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion.
Gorain B; Choudhury H; Tekade RK; Karan S; Jaisankar P; Pal TK
Regul Toxicol Pharmacol; 2016 Dec; 82():20-31. PubMed ID: 27815174
[TBL] [Abstract][Full Text] [Related]
15. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation.
Jadhav P; Gokarna V; Deshpande V; Vavia P
AAPS PharmSciTech; 2020 Sep; 21(7):254. PubMed ID: 32888102
[TBL] [Abstract][Full Text] [Related]
17. COMPARATIVE BIOAVAILABILITY OF A FIXED-DOSE COMBINATION TABLET OF OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE IN HEALTHY KOREAN VOLUNTEERS.
Zheng R; Hwang HM; Kim BH
Acta Pol Pharm; 2016; 73(2):509-16. PubMed ID: 27180444
[TBL] [Abstract][Full Text] [Related]
18. Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability.
Komesli Y; Burak Ozkaya A; Ugur Ergur B; Kirilmaz L; Karasulu E
Drug Dev Ind Pharm; 2019 Aug; 45(8):1292-1305. PubMed ID: 30986085
[TBL] [Abstract][Full Text] [Related]
19. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
Pandya NT; Jani P; Vanza J; Tandel H
Colloids Surf B Biointerfaces; 2018 May; 165():37-44. PubMed ID: 29453084
[TBL] [Abstract][Full Text] [Related]
20. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
